consid
recent
hiv
vaccin
failur
author
believ
would
import
find
new
target
vaccineinduc
immun
analyz
data
previou
trial
use
innov
approach
review
articl
author
briefli
summar
signific
antibodydepend
enhanc
infect
differ
viral
diseas
discuss
role
type
antibodi
obstacl
vaccin
develop
find
indic
complementmedi
antibodydepend
enhanc
cade
present
also
hivinfect
patient
summar
previou
result
author
suggest
cade
play
import
role
progress
hiv
infect
describ
data
reflect
enhanc
antibodi
may
develop
even
vaccin
anim
human
volunt
may
respons
paradox
result
obtain
subgroup
vaccine
discuss
final
base
hypothesi
author
offer
suggest
futur
develop
vaccin
end
difficult
period
hivaid
vaccin
develop
phase
iii
trial
vaccin
aim
rais
steril
antibodymedi
immun
fail
differ
frequenc
breakthrough
infect
vaccin
placebo
arm
trial
type
vaccin
merck
use
differ
strategi
prematur
stop
septemb
merck
vaccin
reli
exclus
stimul
cellular
immun
respons
although
well
known
antibodi
import
prevent
infect
eventu
success
vaccin
rais
antibodymedi
protect
tcell
vaccin
hope
control
level
hiv
bodi
vaccine
long
time
therebi
prevent
progress
aid
unfortun
case
trial
finish
vaccin
provid
protect
infect
also
differ
vaccin
placebo
arm
regard
progress
hiv
diseas
breakthrough
infect
belief
time
draw
lesson
failur
find
new
target
vaccineinduc
immun
analyz
data
trial
perform
far
use
innov
approach
mani
experiment
clinic
data
well
experi
obtain
viral
infect
indic
proport
antibodi
develop
earli
persist
throughout
cours
hiv
infect
traitor
immun
system
instead
contain
elimin
viru
antibodi
facilit
product
bodi
infect
person
enhanc
antibodi
counteract
effect
neutral
antibodi
rel
power
good
guy
versu
bad
guy
balanc
enhanc
neutral
antibodi
decis
progress
hiv
diseas
assum
type
hiv
vaccin
may
rais
enhanc
antibodi
well
antibodi
reduc
efficaci
vaccin
least
hiv
infect
enhanc
antibodi
mostli
exert
effect
activ
complement
system
therefor
balanc
enhancingneutr
antibodi
correctli
measur
presenc
fresh
hiv
seroneg
human
serum
contain
human
complement
gener
virusspecif
antibodi
play
import
role
control
viral
infect
sever
way
certain
instanc
howev
presenc
specif
antibodi
benefici
viru
paradox
process
known
antibodydepend
enhanc
ade
viral
infect
ade
virusspecif
antibodi
enhanc
entri
viru
case
replic
within
cell
monocytesmacrophag
granulocyt
cell
interact
fc
andor
complement
receptor
signific
logfold
even
greater
increas
vitro
product
sever
virus
observ
follow
exposur
lowaffin
antibodi
ade
infect
describ
numer
virus
belong
differ
famili
order
review
common
properti
virus
includ
replic
partial
exclus
macrophag
b
induct
abund
product
antibodi
poorli
neutral
even
homolog
viru
c
caus
persist
infect
commonli
character
prolong
viremia
antigen
divers
isol
anoth
common
featur
render
virus
partial
resist
neutral
antibodi
rais
heterolog
isol
ade
viru
infect
suggest
diseaseenhanc
factor
sever
human
anim
viral
diseas
data
patholog
signific
ade
accumul
dengu
viru
dv
infect
major
case
dv
infect
usual
manifest
mild
febril
diseas
refer
dengu
fever
afflict
patient
recov
day
without
complic
less
frequent
howev
progress
sever
lifethreaten
syndrom
dengu
hemorrhag
fever
dhf
alway
accompani
thrombocytopenia
sometim
frank
hemorrhag
leak
plasma
interstiti
space
result
hypovolemia
sometim
circulatori
collaps
sever
clinic
form
dhf
profound
plasma
leakag
lead
shock
refer
dengu
shock
syndrom
dss
associ
ade
infect
sever
diseas
extens
studi
evid
indic
strong
correl
demonstr
experiment
rhesu
monkey
antidv
matern
antibodi
enhanc
dv
infect
clinic
set
greater
risk
develop
dss
demonstr
children
specif
matern
antibodi
patient
previous
infect
either
four
dv
serotyp
subsequ
expos
strain
viru
accordingli
found
dv
produc
sever
clinic
manifest
older
individu
subneutr
level
antibodi
induc
previou
dv
infect
individu
never
expos
viru
addit
casecontrol
studi
demonstr
presenc
dv
antibodi
signific
risk
factor
increas
sever
diseas
mortal
dhfdss
sever
import
prospect
seroepidemiolog
studi
conduct
area
endem
dhfdss
reveal
immunopatholog
event
lead
develop
diseas
follow
reinfect
dengu
viru
differ
serotyp
sever
diseas
associ
high
level
antibodyenhanc
viral
replic
earli
cours
diseas
follow
cascad
memori
tcell
activ
storm
inflammatori
cytokin
chemic
mediat
compound
mainli
releas
cell
monocytesmacrophag
endotheli
cell
eventu
increas
vascular
permeabl
mechan
ade
evid
vitro
vivo
studi
strongli
suggest
viral
replic
fcreceptor
bear
cell
especi
monocyt
macrophag
enhanc
preexist
subneutr
nonprotect
concentr
dengu
igg
antibodi
enhanc
replic
dv
target
cell
lead
high
level
viremia
earli
stage
ill
correl
dhfdss
incid
addit
igg
igm
type
antibodi
enhanc
dv
infect
via
complement
receptor
also
implic
besid
dengu
viru
infect
ade
found
affect
cours
lifethreaten
infecti
disord
human
sever
respiratori
syntiti
viru
rsv
infect
young
children
found
associ
presenc
matern
antibodi
observ
support
also
anim
experi
monkey
immun
inactiv
rsv
vaccin
infect
viru
extent
infect
well
patholog
score
higher
immun
control
anim
accord
recent
data
ade
may
import
role
pathogenesi
ebolaviru
infect
well
takada
et
al
show
human
ebola
zair
viru
infect
induc
antibodi
enhanc
vitro
infect
zair
ebola
viru
speci
interestingli
enhanc
mediat
antibodi
viral
glycoprotein
complement
compon
author
suggest
ade
may
respons
extrem
virul
zair
viru
among
four
ebola
viru
speci
addit
ade
infect
also
implic
major
obstacl
develop
vaccin
virus
dengu
virus
bluetongu
viru
influenza
viru
lentivirus
rsv
review
case
presenc
antibodi
induc
vaccin
increas
suscept
subsequ
viral
infect
andor
enhanc
sever
clinic
diseas
caus
viru
challeng
vaccin
individu
recent
ade
implic
pathogenesi
atyp
morbilli
viru
infect
observ
immun
formalininactiv
vaccin
suggest
concern
develop
vaccin
sever
acut
respiratori
syndrom
sar
well
antibodi
may
enhanc
hiv
infect
vitro
describ
shortli
hiv
first
isol
presenc
blood
hivinfect
patient
well
hivor
sivinfect
experiment
anim
confirm
sever
group
two
type
enhanc
antibodi
describ
approxim
time
late
eighti
robinson
et
al
found
sera
hivinfect
individu
enhanc
vitro
hiv
infect
complement
receptor
type
bear
lymphoblastoid
cell
line
author
demonstr
enhanc
depend
antibodi
mediat
complement
coin
name
complementmedi
antibodydepend
enhanc
cade
gra
dormont
could
reproduc
phenomenon
peripher
blood
lymphocyt
accord
studi
cade
infect
character
increas
synthesi
protein
rna
well
enhanc
releas
infect
virus
fcrade
abil
heatinactiv
sera
hivseroposit
patient
igg
purifi
sera
acceler
andor
enhanc
product
hiv
cell
infect
mixtur
contain
antibodi
first
describ
takeda
et
al
homsi
et
al
shortli
thereaft
fcrade
infect
observ
vitro
mani
differ
isol
phenotyp
use
differ
target
cell
review
except
earli
work
fcrade
data
clinic
signific
report
cade
therefor
follow
discuss
larg
restrict
latter
type
infectionenhanc
light
recent
observ
indic
antibodi
bind
fc
receptor
complement
mediat
antibodydepend
protect
hiv
domin
role
cade
enhanc
seem
surpris
cade
mediat
mostli
antibodi
ntermin
end
contain
socal
immunodomin
domain
protein
although
role
exclud
either
two
domain
amino
acid
map
mean
monoclon
antibodi
main
bind
site
cade
antibodi
character
use
sitedirect
mutagenesi
mitchel
et
al
mechan
cade
investig
sever
studi
last
two
decad
summar
recent
robinson
bind
antibodi
initi
complement
cascad
lead
deposit
complement
compon
g
virion
opson
virion
subsequ
bind
complement
receptor
type
ultim
engag
receptor
opson
virion
lead
increas
rate
hiv
spread
tissu
cultur
tenfold
increas
releas
revers
transcriptas
rt
cultur
medium
well
increas
level
hiv
genom
rna
importantli
cade
lead
almost
increas
number
infect
progeni
viru
synthes
compar
infect
alon
cade
infect
requir
bind
virion
may
also
increas
cade
accord
recent
studi
robinson
coreceptor
also
requir
addit
complement
receptor
enhanc
entri
hiv
cell
find
experiment
animaland
human
studi
indic
cade
may
strongli
associ
progress
siv
hiv
diseas
previou
studi
shown
passiv
immun
rhesu
macaqu
antibodi
chronic
infect
monkey
could
lead
enhanc
pathogenesi
inocul
moreov
diseas
progress
immun
correl
titer
antibodi
direct
enhanc
domain
passiv
activ
immun
studi
word
higher
titer
antibodi
primari
enhanc
domain
faster
anim
proceed
aid
sever
find
group
other
indic
cade
correl
progress
hiv
diseas
well
use
method
describ
first
studi
measur
cade
briefli
serum
sampl
patient
heattreat
c
min
dilut
cultur
medium
test
serum
dilut
mix
ident
volum
fresh
pool
sera
hivseroneg
healthi
person
iiib
tcid
ad
incub
c
h
mixtur
ad
incub
togeth
cell
without
chang
day
c
growth
hiv
cultur
monitor
day
revers
transcriptas
rt
assay
result
measur
count
per
minut
express
final
index
enhancementneutr
index
en
valu
en
index
ratio
viru
growth
presenc
absenc
test
serum
sampl
en
ie
twofold
decreas
viru
product
consid
neutral
wherea
sampl
en
ie
twofold
increas
viru
product
consid
enhanc
method
two
major
benefit
use
almost
physiolog
complement
concentr
infect
mixtur
viru
product
measur
rt
assay
measur
infect
virus
appar
drawback
measur
perform
system
seem
singl
celladapt
strain
iiib
use
experi
clinic
sampl
wherea
system
use
primari
isol
assay
primari
cell
essenti
vivo
relev
recent
eleg
studi
mitchel
et
al
robinson
help
resolv
appar
paradox
situat
accord
mitchel
et
al
primari
antigen
domain
respons
cade
hiv
siv
conserv
sequenc
critic
interact
even
importantli
robinson
found
antihiv
immunoglobulinenhanc
replic
hiv
strain
belong
differ
clade
indic
antibodi
mediat
cade
broadli
reactiv
method
obtain
evid
indic
cade
occur
earli
cours
hiv
infect
strongli
associ
predict
progress
hiv
diseas
use
four
differ
seroconvers
plasma
panel
boston
biomedica
cultur
infect
plasmavirushuman
complement
mixtur
mark
rise
eni
observ
four
panel
valu
reach
index
valu
correspond
time
enhanc
viru
product
concomitantli
seroconvers
approxim
day
post
infect
furthermor
associ
gener
increas
antigenemia
appear
rna
fig
result
one
seroconvers
panel
hiv
rna
level
detect
undetect
also
shown
adapt
contrast
cultur
infect
virusserum
mixtur
without
complement
eni
valu
lower
observ
timepoint
seroconvers
panel
studi
perform
patient
advanc
hiv
diseas
patient
center
diseas
control
prevent
cdc
stage
iii
iva
patient
cdc
stage
ivb
ivc
found
strong
correl
eni
extent
enhanc
neutral
one
hand
viral
load
spearman
rank
correl
coeffici
calcul
viral
load
measur
amplicor
nasba
method
p
r
p
respect
contrast
much
weaker
correl
p
r
p
respect
found
cultur
infect
mixtur
contain
heatinactiv
serum
activ
complement
viral
load
sampl
neutral
en
index
neutral
enhanc
en
index
enhanc
en
index
hiv
product
presenc
complement
compar
parallel
signific
kruskallw
test
p
increas
observ
fig
found
neg
correl
en
indic
cell
count
spearman
rank
correl
coeffici
p
twelv
serum
sampl
aid
patient
wherea
sampl
asymptomat
case
en
index
convers
none
aid
patient
sampl
sampl
asymptomat
patient
neutral
hiv
presenc
complement
recent
subbramanian
et
al
report
quit
similar
find
found
cade
mediat
antibodi
patient
hiv
diseas
titer
antibodi
higher
patient
aid
asymptomat
infect
contrast
neutral
presenc
complement
could
detect
sera
asymptomat
patient
predominantli
importantli
neutral
assay
perform
presenc
complement
predict
develop
aid
asymptomat
hiv
patient
median
followup
period
month
fig
test
perform
absenc
complement
predict
valu
similar
result
obtain
adapt
declin
cell
count
compar
patient
without
neutral
presenc
complement
addit
en
valu
rna
level
increas
significantli
observ
period
hivinfect
patient
remain
untreat
aztmonotherapi
recent
measur
chang
en
indic
patient
undergo
haart
substanti
proport
sampl
obtain
begin
haart
enhanc
viru
product
presenc
complement
neutral
rare
sera
obtain
patient
month
haart
treatment
neutral
hiv
even
presenc
complement
fig
median
percentil
valu
en
drop
significantli
p
en
followup
period
haart
comparison
cultur
inocul
mixtur
hiv
purifi
igg
prepar
serum
pool
taken
haart
also
reveal
markedli
decreas
eni
valu
sharp
contrast
find
clinic
use
measur
cea
challeng
montefiori
group
find
differ
frequenc
neutral
enhanc
antibodi
measur
presenc
complement
patient
differ
stage
hiv
diseas
addit
longterm
nonprogressor
state
similarli
associ
lack
enhanc
antibodi
main
differ
method
procedur
final
concentr
human
complement
mixtur
ad
target
cell
complement
concentr
experi
montefiori
group
use
concentr
seem
reason
suppos
closer
experiment
condit
vivo
condit
higher
patholog
relev
measur
thu
mani
data
indic
natur
cours
hiv
infect
mixtur
differ
antibodi
present
blood
patient
type
antibodi
may
antagon
antibodi
type
detail
enhanc
antibodi
appear
earlier
hiv
infect
neutral
antibodi
furthermor
balanc
good
bad
antibodi
chang
progress
hiv
diseas
bad
enhanc
antibodi
becom
predomin
advanc
stage
issu
address
eleg
studi
subbramanian
et
al
author
measur
parallel
concentr
virusneutr
antibodi
na
na
presenc
complement
cna
well
antibodydepend
cellular
cytotoxicitymedi
adcc
antibodi
infectionenhanc
antibodi
presenc
absenc
complement
cade
versu
fcrade
antibodi
may
control
hiv
progress
na
cna
adcc
found
mainli
asymptomat
patient
wherea
aid
stage
balanc
shift
toward
infectionenhanc
fcrade
cade
antibodi
find
rais
possibl
infectionenhanc
antibodi
develop
experiment
anim
volunt
immun
candid
hiv
vaccin
similarli
seem
plausibl
similarli
natur
infect
may
abrog
benefici
effect
neutral
adccmedi
antibodi
certain
data
sivmonkey
model
hiv
vaccin
trial
indic
may
inde
occur
antibodi
put
siv
infectionenhanc
domain
diminish
benefici
effect
siv
vaccin
rhesu
macaqu
verrier
et
al
demonstr
hyperimmun
rhesu
macaqu
whole
viru
particlebas
vaccin
play
facilit
role
transmiss
viru
andor
evolut
diseas
recent
passiv
immun
studi
siv
immunoglobulin
decreas
plasma
viremia
delay
diseas
progress
four
monkey
six
howev
remain
two
anim
group
higher
viral
load
peripher
blood
cell
control
anim
progress
rapidli
control
anoth
recent
experi
conduct
rhesu
macaqu
immun
recombin
varicellazost
viru
vaccin
express
hiv
receiv
vaccin
rais
high
amount
nonneutr
antibodi
manifest
increas
level
siv
replic
rapid
deplet
acceler
progress
aid
compar
control
observ
indic
candid
aid
vaccin
may
simpli
either
efficaci
neutral
may
also
potenti
harm
seem
highli
probabl
enhanc
antibodi
may
develop
human
volunt
immun
candid
hiv
vaccin
exampl
complementdepend
enhanc
antibodi
detect
two
trial
volunt
subject
vaccin
high
dose
g
candid
vaccin
indirect
evid
indic
enhanc
type
antibodi
could
develop
recent
phase
iii
vaccin
trial
well
gilbert
et
al
recent
report
correl
immunolog
respons
recombin
vaccin
incid
infect
phase
vaccin
trial
found
vaccine
develop
low
antibodi
respons
slightli
significantli
higher
chanc
becom
infect
placebo
recipi
caucasian
recipi
odd
ratio
high
p
p
mn
block
antibodi
respect
hand
even
high
antibodi
respons
appear
fail
protect
vaccine
infect
author
put
forward
two
altern
explan
find
vaccin
induc
immun
respons
enhanc
suscept
infect
low
respond
b
differ
antibodi
respons
mere
identifi
divers
capabl
vaccine
resist
infect
discuss
paper
weigh
rel
plausibl
two
explan
could
decid
accord
editori
comment
graham
mascola
would
like
discuss
possibl
corrobor
abund
literatur
data
summar
antibodymedi
enhanc
may
develop
diminish
abrog
benefici
effect
vaccin
even
harm
vaccin
volunt
believ
risk
serious
consid
futur
develop
vaccin
find
summar
indic
balanc
good
neutral
adcc
mediat
bad
infectionenhanc
antibodi
strongli
correl
possibl
one
drive
forc
behind
progress
hiv
diseas
suppos
find
obtain
hivinfect
person
may
relev
vaccin
trial
well
base
assumpt
would
like
put
forward
four
propos
sinc
exclud
hiv
vaccin
increas
likelihood
infect
propos
serum
sampl
obtain
vaccin
placebotr
volunt
breakthrough
infect
major
vaccin
trial
test
cade
fcrade
accord
propos
robinson
also
suggest
avoid
inclus
whole
least
major
epitop
cade
hiv
vaccin
reinvestig
epitop
respons
develop
differ
type
enhanc
antibodi
approach
may
possibl
develop
prevent
vaccin
strong
neutral
weak
ade
induc
characterist
base
literatur
data
refer
indic
neutral
assay
perform
presenc
complement
exhibit
much
stronger
correl
diseas
progress
tradit
test
propos
use
altern
tradit
method
measur
neutral
antibodi
order
find
effect
vaccin
reason
assum
measur
balanc
neutral
enhanc
antibodi
presenc
complement
may
reflect
also
proport
protect
antiprotect
antibodi
present
vaccine
method
easili
adapt
anim
experi
therefor
may
prove
use
earli
select
candid
vaccin
elimin
potenti
harm
vaccin
also
believ
measur
viru
product
cell
infect
presenc
antibodi
complement
may
provid
better
immun
correl
current
